Adjuvant nivolumab has significantly improved survival for patients with resected esophageal cancer who have residual disease after neoadjuvant therapy. However, managing the **adjuvant nivolumab recurrence risk** remains a significant hurdle in clinical practice. A recent real-world study published in the *Annals of Surgical Oncology* evaluates the specific prognostic factors that influence these outcomes in a clinical setting.

The study analyzed 82 patients, primarily those with esophageal squamous cell carcinoma (ESCC). These patients underwent preoperative therapy followed by minimally invasive esophagectomy. Results indicated a median recurrence-free survival (RFS) of 30.8 months. Despite the known benefits of immunotherapy, 54% of the cohort experienced recurrence during the median follow-up of 30.6 months. Notably, 37% of patients developed recurrence while still receiving the adjuvant therapy.

Identifying High Adjuvant Nivolumab Recurrence Risk

Researchers identified several independent risk factors through multivariable analysis. Specifically, patients with ypN3 disease and a poor response to preoperative therapy faced a significantly higher likelihood of recurrence. Furthermore, the pretreatment prognostic nutritional index (PNI) served as a critical indicator. Consequently, clinicians should monitor these specific patient subsets more closely to detect early signs of treatment failure.

Nutritional status is increasingly recognized as a vital component of immunotherapy success in gastrointestinal cancers. Because the PNI reflects both systemic inflammation and nutritional reserves, it helps predict how well a patient might respond to adjuvant nivolumab. Therefore, integrating aggressive nutritional support might potentially mitigate some risks associated with postoperative recurrence. Clinicians must balance these clinical markers with the standard pathological staging to stratify patients effectively after surgery.

Frequently Asked Questions

What is the median recurrence-free survival for these patients?

In this real-world study, the median recurrence-free survival (RFS) was approximately 30.8 months for patients receiving adjuvant nivolumab.

Which pathological factors increase the risk of recurrence?

Key risk factors include ypN3 disease and a poor pathological response to neoadjuvant therapy prior to surgical resection.

Why is the Prognostic Nutritional Index (PNI) important?

The PNI is an independent risk factor for recurrence; a lower index indicates poor nutritional and immunological status, which may reduce the efficacy of immunotherapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sugase T et al. Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study. Ann Surg Oncol. 2026 Apr 14. doi: 10.1245/s10434-026-19648-4. PMID: 41979848.

Kelly RJ, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.

Ikoma T, et al. Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab. Cancer Immunol Immunother. 2023;72(2):427-435. doi: 10.1007/s00262-022-03265-7.

"